Blood inflammatory phenotypes were associated with distinct clinical expressions of asthma in adults from a large population-based cohort.

Autor:	Tsiavia T; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Équipe d'Épidémiologie Respiratoire Int´grative, CESP, 94807, Villejuif, France. Electronic address: tajidine.tsiavia@inserm.fr., Henny J; Université Paris-Saclay, UVSQ, Inserm, Cohortes Epidémiologiques en population, 94807, Villejuif, France., Goldberg M; Université Paris-Saclay, UVSQ, Inserm, Cohortes Epidémiologiques en population, 94807, Villejuif, France; Faculté de Médecine, Univ. de Paris, Paris, France., Zins M; Université Paris-Saclay, UVSQ, Inserm, Cohortes Epidémiologiques en population, 94807, Villejuif, France; Faculté de Médecine, Univ. de Paris, Paris, France., Roche N; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Équipe d'Épidémiologie Respiratoire Int´grative, CESP, 94807, Villejuif, France; Respiratory Medicine, Pneumologie et Soins Intensifs Respiratoires, APHP Centre, Cochin Hospital, Université de Paris (Descartes), Institut Cochin (UMR 1016), Paris, France., Orsi L; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Équipe d'Épidémiologie Respiratoire Int´grative, CESP, 94807, Villejuif, France., Nadif R; Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Équipe d'Épidémiologie Respiratoire Int´grative, CESP, 94807, Villejuif, France.
Jazyk:	angličtina
Zdroj:	EBioMedicine [EBioMedicine] 2022 Feb; Vol. 76, pp. 103875. Date of Electronic Publication: 2022 Feb 10.
DOI:	10.1016/j.ebiom.2022.103875
Abstrakt:	Background: Asthma is an inflammatory heterogeneous disease. Asthma inflammatory phenotypes based on blood eosinophil and neutrophil counts have never been identified and characterized in population-based studies. Methods: Adults with current asthma and available blood eosinophil and neutrophil counts from the French population-based CONSTANCES cohort were included. Current asthma was defined by reports of asthma attacks, symptoms or treatments in the last 12 months. Inflammatory phenotypes were based on low (L) and high (H) blood (B) eosinophil (E) (LBE/HBE: 9 /L, respectively) and neutrophil (N) (LBN/HBN: 9 /L, respectively) cut-offs. Associations between inflammatory phenotypes and the clinical expressions of asthma were studied using logistic models adjusted for age, sex, smoking status, body mass index, education level, French deprivation index and treatment. Other cut-offs were applied. Stratified analyses according to age or sex were performed. Findings: Among 15,019 adults with asthma (56% women, 59%≥40 years), the LBE/LBN (reference), LBE/HBN, HBE/LBN and HBE/HBN phenotypes accounted for 57%, 6%, 33% and 4% respectively. The LBE/HBN phenotype was associated with being awaken by an attack of coughing, chronic bronchitis, and dyspnoea (adjusted(a)OR ranging from 1·21 to 1·42). The HBE/LBN and HBE/HBN phenotypes were associated with asthma attacks (aOR=1·31[1·20-1·42], 1·25[1·02-1·53]) and asthma symptom score (p for trend<0·0001, p for trend=0·001, respectively). The HBE/LBN phenotype was also associated with being awaken with chest tightness (aOR=1·30[1·20-1·40]). Results were unchanged whatever the cut-offs used. No statistically significant heterogeneity was observed according to age or sex. Interpretation: Differences in the clinical expressions of asthma were found between the phenotypes, reproducible whatever the cut-offs used, and similar to those observed in case-control and clinical studies. Such phenotypes are of interest to improve asthma management and study its environmental risk factors. Funding: The CONSTANCES cohort receives grants from ANR (ANR-11-INBS-0002), the Caisse nationale d'assurance maladie-CNAM and the Ministry of research. CONSTANCES also receives funding from MSD, AstraZeneca, Lundbeck and L'Oréal, managed by INSERM-Transfert. T.Tsiavia is supported by a PhD grant from the Fondation pour le Recherche Médicale (ECO202006011654). Competing Interests: Declaration of interests Dr. N.Roche reports grants and personal fees from GSK, Boehringer Ingelheim, Pfizer and Novartis; personal fees from Teva, AstraZeneca, Chiesi, Sanofi and Zambon outside the submitted work. The other authors declare no potential conflicts of interest. (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu